Please login to the form below
Orion
This page shows the latest Orion news and features for those working in and with pharma, biotech and healthcare.
UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients
Professor Kausik Ray of Imperial College London, who was lead investigator on the pivotal ORION-10 and ORION-11 trials for Leqvio, said that the drug brought LDL-C levels down
Latest news
-
Novartis announces delay in UK cholesterol drug study
In January 2020, Novartis announced that it had teamed up with the UK’s National Health Service (NHS) on a clinical trial – ORION-4 – of the drug. ... Tsai addressed the ORION-4 delays amid a discussion of Novartis’ first quarter results for 2021.
-
Janssen’s Erleada improves survival in certain advanced prostate cancer patients
Bayer/Orion’s Nubeqa (darolutamide) is a more recent competitor and it has been approved for the treatment of nmCRPC in men.
-
Novartis scores CHMP backing for cholesterol drug Leqvio
The positive opinion is based on results from Novartis’ ORION clinical research programme, including phase 3 trials which involved over 3, 600 patients on a maximum statin dose. ... Another trial, dubbed ORION-4, is currently underway to determine if
-
Bayer gets EU nod for prostate cancer drug Nubeqa
Enters an increasingly competitive market. Bayer and Orion have bagged approval from the European Commission (EC) for their new prostate cancer treatment Nubeqa, setting it up to rival other approved treatments ... Bayer and Orion reckon they have an
-
Novartis plans inclisiran trial in the UK
Novartis also plans to conduct ORION-4, the ongoing study for patients who have already had a heart attack or stroke, with this study making the UK the global trial centre.
More from news
Approximately 2 fully matching, plus 34 partially matching documents found.
Latest Intelligence
-
Deal Watch table for June 2014
75. Orion/ Bayer. Co-development, option to co-promote in Europe. OraQuick HCV rapid test in US.
-
Pharma deals during June 2014
Financial terms were not disclosed but include milestone and royalties. Staying with the mid-caps and turning to prostate cancer, Bayer and Orion entered into a joint development deal for ... The companies will jointly fund the phase III trials. Orion
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Orion appoints VP of oncology, R&D
He said: “My new position at Orion allows me to maintain and deepen my research focus, which is to develop such treatments for cancer patients wherever they live. ... I hope that my long background in the academia will help in the initiation of new
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest from PMHub
-
Leading NHS suppliers highlighted in shortlist for new HSJ awards
Philips. Intercity Technology. Orion Health and Temple Street Children’s University Hospital.
-
Creative Medical Research
Address:. 9 Pegasus. Orion Court , Great Blakenham. Ipswich. IP6 0LW.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Account Executive, Medical/ Brand Communications, London
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
-
Consultant Dermatologist (Freelance)
-
£110-180ph
-
Head of Health Psychology, London
-
Highly competitive salary
-
Senior Health Psychologist, London
-
Highly competitive salary
- Recognising HIV Vaccine Awareness Day
- Scientists discover new approach to treat brain tumours
- Boehringer Ingelheim’s pulmonary fibrosis treatment produces promising phase 2 data
- NICE recommends AstraZeneca’s Imfinzi for adults with non-small cell lung cancer
- Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients
- J&J appoints Thibaut Mongon as CEO designate of New Consumer Health Company
- Live Webinar: The Future of MedTech: Streamlined Clinical Data Collection & Management
- Medscape: Connect to the conversation
- A Medscape 4-part video interview series
- Why big pharma needs to be braver
- MadMicrobe Studios Inc Announces New European Venture
- EMA accepts Valneva’s marketing authorisation application for COVID-19 vaccine
PMHub
3 Monkeys Zeno
3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...
Latest intelligence
- Why big pharma needs to be braver
- The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
- Leveraging Real-World Evidence for Cell and Gene Therapies
- Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
- Food Allergy – Is avoidance the only option?
- Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...
